Biosafety assessment of engineered CCL20 locked dimers in vivo
Donovan Drouillard, Maria Poimenidou, Marissa Davies, Donna McAllister, William R Clarke, Samuel T Hwang, Francis C Peterson, Brian F Volkman, Michael B Dwinell · 2025
Read Biosafety assessment of engineered CCL20 locked dimers in vivo by Donovan Drouillard, Maria Poimenidou, Marissa Davies, Donna McAllister, William R Clarke, Samuel T Hwang, Francis C Peterson, Brian F Volkman, Michael B Dwinell (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12799736.txt.
Description
Drouillard and a large team tested in twenty twenty-five if a locked pair form of a signal protein is safe in live animals. The protein, CCL20, calls defense cells to a spot through its switch. Locked pairs can block that switch with more aim than broad drugs.
They gave the locked form by shot each day for two weeks at doses that had helped in skin ill tests. No weight loss or broad defense loss was seen. Blood, urine, and organ checks were near normal at most doses. The top dose grew the spleen a bit, and one dose mildly shook a cell-aid path. The team sees a wide safe range.
Catalog record
| CREATOR | Donovan Drouillard, Maria Poimenidou, Marissa Davies, Donna McAllister, William R Clarke, Samuel T Hwang, Francis C Peterson, Brian F Volkman, Michael B Dwinell |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 51 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |